U.S. Markets closed

Repligen Corporation (RGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
171.96+2.31 (+1.36%)
At close: 4:00PM EDT

Repligen Corporation

Building 1
Suite 100 41 Seyon Street
Waltham, MA 02453
United States
781 250 0111
http://www.repligen.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full Time Employees1,128

Key Executives

NameTitlePayExercisedYear Born
Mr. Anthony J. HuntCEO, Pres & Director1.11M15.94M1964
Mr. Jon K. SnodgresChief Financial Officer693.79k1.97M1966
Mr. Ralf KuriyelSr. VP of R&D645.25k1.36M1959
Mr. James R. BylundSr. VP of Global Operations & Information TechnologyN/AN/A1963
Ms. Sondra S. NewmanGlobal Head of Investor RelationsN/AN/AN/A
Mr. Squire ServanceSr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance OfficerN/AN/AN/A
Mr. Stephen TingleyVP of Global SalesN/AN/AN/A
Ms. Rachel GoodrichVP of MarketingN/AN/AN/A
Mr. Ken ElmerGlobal Head of HRN/AN/AN/A
Ms. Christine GebskiSr. VP of Filtration & ChromatographyN/AN/A1968
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Repligen Corporation’s ISS Governance QualityScore as of April 30, 2021 is 3. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.